PRESS RELEASE




Inventiva Announces the Appointment of Renée Aguiar-
Lucander to its Board of Directors

Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq:
IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of
oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced
the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by
shareholders at the recent Company’s Annual General Meeting.

Mark Pruzanski, Chairman of Inventiva: “We are thrilled to welcome Renée to the Board at this pivotal moment
in Inventiva’s journey. Her exceptional track record in our industry speaks for itself and will be key as we enter the
final stages of clinical development for lanifibranor and prepare for its potential approval and launch.”

Renée Aguiar-Lucander: “I’m honored to have the opportunity to join Inventiva’s Board. With the NATiV3 Phase 3
trial fully enrolled, I look forward to working with the team to potentially bring lanifibranor to patients with
MASH.”

Mrs. Aguiar-Lucander has served as the Chief Executive Officer of Hansa Biopharma since April 2025. She was
previously Chief Executive Officer of Calliditas Therapeutics, where she led the transformation of the company
from a small biotech company into a NASDAQ-listed, commercial-stage leader in rare diseases, culminating in its
$1.1 billion acquisition by Asahi Kasei in 2024. Under her leadership, Calliditas achieved the first-ever FDA approval
for a treatment in IgA nephropathy (TARPEYO®) and successfully launched the product in the U.S. Prior to her role
at Calliditas, Ms. Aguiar-Lucander held various senior roles in the field of life sciences investment and corporate
finance, including Partner and COO at Omega Fund Management and Managing Director at a global investment
bank. She holds an MBA from INSEAD and a BA in Finance from the Stockholm School of Economics.


About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical
need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3
clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN:
FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
http://www.inventivapharma.com


Contacts

Inventiva Brunswick Group ICR Healthcare
Pascaline Clerc Tristan Roquet Montegon / Patricia L. Bank
EVP, Strategy and Corporate Affairs Aude Lepreux / Investor relations
media@inventivapharma.com Julia Cailleteau patti.bank@icrhealthcare.com
+1 202 499 8937 Media relations +1 415 513 1284
inventiva@brunswickgroup.com
+33 1 53 96 83 83



1
COMMUNIQUE DE PRESSE



Important Notice

This press release contains certain “forward-looking statements” within the meaning of the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts,
included in this press release are forward-looking statements. These statements include, but are not limited to,
Inventiva’s clinical trials, including Inventiva’s ongoing NATiV3 Phase 3 clinical trial of lanifibranor in MASH,
including related timing and regulatory matters, Inventiva’s pipeline development plans, the clinical development
of and regulatory plans and pathway for lanifibranor, and future activities, expectations, plans, growth and
prospects of Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words
such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”,
“will”, “would”, “could”, “might”, “should”, “designed”, “hopefully”, “target”, “potential”, “possible”, “aim”, and
“continue” and similar expressions. Such statements are not historical facts but rather are statements of future
expectations and other forward-looking statements that are based on management's beliefs. These statements
reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown
risks and uncertainties that could cause future results, performance, or future events to differ materially from
those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors
that are beyond Inventiva's control. There can be no guarantees with respect to product candidates that the clinical
trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated,
that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones
by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be
materially different from the anticipated future results, performance or achievements expressed or implied by such
statements, forecasts and estimates due to a number of factors, including that interim data or data from any
interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the
DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts
of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory
matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no
historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has never generated
any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence
of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or
development programs or be unable to expand its operations or otherwise capitalize on its business opportunities
and may be unable to continue as a going concern, Inventiva’s ability to obtain financing, to enter into potential
transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval
and subsequent commercialization of lanifibranor, preclinical studies or earlier clinical trials are not necessarily
predictive of future results and the results of Inventiva's and its partners’ clinical trials may not support Inventiva's
and its partners’ product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to
be wrong and regulatory authorities may require additional holds and/or amendments to Inventiva’s clinical trials,
Inventiva’s expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH
may not be realized and may not support the approval of a New Drug Application, Inventiva’s ability to identify
additional products or product candidates with significant commercial potential, Inventiva’s expectations with
respect to its pipeline prioritization plan and related workforce reduction, including whether the plan will be
implemented and the timing, potential benefits, expenses and consequences relating thereto, Inventiva’s ability
to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva’s ability to
successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any
agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships
on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates,
and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter
substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the
satisfaction of applicable regulatory authorities, the ability of Inventiva and its partners to recruit and retain
patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming
process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its
partners’ control, Inventiva's product candidates may cause adverse drug reactions or have other properties that
could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial

2
COMMUNIQUE DE PRESSE



competition and Inventiva’s and its partners' business, and pre-clinical studies and clinical development programs
and timelines, its financial condition and results of operations could be materially and adversely affected by
changes in law and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict
between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger
conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies,
global inflation, financial and credit market fluctuations, tariffs and other trade barriers, political turmoil and
natural catastrophes, uncertain financial markets and disruptions in banking systems, and the vote of Inventiva’s
shareholders. The review of potential financial and strategic options may not result in any particular action or
transaction being pursued, entered into or consummated, and there is no assurance as to the timing, sequence or
outcome of any action or transaction or series of actions or transactions. Given these risks and uncertainties, no
representations are made as to the accuracy or fairness of such forward-looking statements, forecasts, and
estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this
press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the year ended December 31, 2024, filed with the Autorité
des Marchés Financiers on April 15, 2025, and the Annual Report on Form 20-F for the year ended December 31,
2024, filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2025 for other risks and
uncertainties affecting Inventiva, including those described under the caption “Risk Factors” and in future filings
with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-
looking statements and may cause actual results and the timing of events to differ materially from those
anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva
has no intention and is under no obligation to update or review the forward-looking statements referred to above.
Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above
statements.




3